Share-based Payment Arrangement, Expense of X4 Pharmaceuticals, Inc from 31 Dec 2016 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
X4 Pharmaceuticals, Inc quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 31 Dec 2016 to 30 Sep 2025.
  • X4 Pharmaceuticals, Inc Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $760,000, a 58% decline year-over-year.
  • X4 Pharmaceuticals, Inc Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $4,244,000, a 50% decline year-over-year.
  • X4 Pharmaceuticals, Inc annual Share-based Payment Arrangement, Expense for 2024 was $8,204,000, a 5.6% decline from 2023.
  • X4 Pharmaceuticals, Inc annual Share-based Payment Arrangement, Expense for 2023 was $8,687,000, a 67% increase from 2022.
  • X4 Pharmaceuticals, Inc annual Share-based Payment Arrangement, Expense for 2022 was $5,199,000, a 16% decline from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

X4 Pharmaceuticals, Inc Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $4,244,000 $760,000 -$1,060,000 -58% 01 Jul 2025 30 Sep 2025 10-Q 05 Nov 2025 2025 Q3
Q2 2025 $5,304,000 $748,000 -$1,680,000 -69% 01 Apr 2025 30 Jun 2025 10-Q 08 Aug 2025 2025 Q2
Q1 2025 $6,984,000 $519,000 -$1,220,000 -70% 01 Jan 2025 31 Mar 2025 10-Q 01 May 2025 2025 Q1
Q4 2024 $8,204,000 $2,217,000 -$322,000 -13% 01 Oct 2024 31 Dec 2024 10-K 26 Mar 2025 2024 FY
Q3 2024 $8,526,000 $1,820,000 -$541,000 -23% 01 Jul 2024 30 Sep 2024 10-Q 05 Nov 2025 2025 Q3
Q2 2024 $9,067,000 $2,428,000 +$286,000 +13% 01 Apr 2024 30 Jun 2024 10-Q 08 Aug 2025 2025 Q2
Q1 2024 $8,781,000 $1,739,000 +$94,000 +5.7% 01 Jan 2024 31 Mar 2024 10-Q 01 May 2025 2025 Q1
Q4 2023 $8,687,000 $2,539,000 +$1,432,000 +129% 01 Oct 2023 31 Dec 2023 10-K 26 Mar 2025 2024 FY
Q3 2023 $7,255,000 $2,361,000 +$1,250,000 +113% 01 Jul 2023 30 Sep 2023 10-Q 13 Nov 2024 2024 Q3
Q2 2023 $6,005,000 $2,142,000 +$620,000 +41% 01 Apr 2023 30 Jun 2023 10-Q 08 Aug 2024 2024 Q2
Q1 2023 $5,385,000 $1,645,000 +$186,000 +13% 01 Jan 2023 31 Mar 2023 10-Q 07 May 2024 2024 Q1
Q4 2022 $5,199,000 $1,107,000 -$502,000 -31% 01 Oct 2022 31 Dec 2022 10-K 26 Mar 2025 2024 FY
Q3 2022 $5,701,000 $1,111,000 -$405,000 -27% 01 Jul 2022 30 Sep 2022 10-Q 09 Nov 2023 2023 Q3
Q2 2022 $6,106,000 $1,522,000 -$275,000 -15% 01 Apr 2022 30 Jun 2022 10-Q 10 Aug 2023 2023 Q3
Q1 2022 $6,381,000 $1,459,000 +$201,000 +16% 01 Jan 2022 31 Mar 2022 10-Q 04 May 2023 2022 Q3
Q4 2021 $6,180,000 $1,609,000 +$211,000 +15% 01 Oct 2021 31 Dec 2021 10-K 21 Mar 2024 2023 FY
Q3 2021 $5,969,000 $1,516,000 -$728,000 -32% 01 Jul 2021 30 Sep 2021 10-Q 03 Nov 2022 2022 Q3
Q2 2021 $6,697,000 $1,797,000 +$624,000 +53% 01 Apr 2021 30 Jun 2021 10-Q 04 Aug 2022 2022 Q2
Q1 2021 $6,073,000 $1,258,000 +$645,000 +105% 01 Jan 2021 31 Mar 2021 10-Q 12 May 2022 2022 Q1
Q4 2020 $5,428,000 $1,398,000 +$734,000 +111% 01 Oct 2020 31 Dec 2020 10-K 21 Mar 2023 2022 FY
Q3 2020 $4,694,000 $2,244,000 +$1,553,000 +225% 01 Jul 2020 30 Sep 2020 10-Q 04 Nov 2021 2021 Q3
Q2 2020 $3,141,000 $1,173,000 +$740,000 +171% 01 Apr 2020 30 Jun 2020 10-Q 03 Aug 2021 2021 Q2
Q1 2020 $2,401,000 $613,000 +$351,000 +134% 01 Jan 2020 31 Mar 2020 10-Q 06 May 2021 2021 Q1
Q4 2019 $2,050,000 $664,000 +$376,000 +131% 01 Oct 2019 31 Dec 2019 10-K 17 Mar 2022 2021 FY
Q3 2019 $1,674,000 $691,000 +$493,000 +249% 01 Jul 2019 30 Sep 2019 10-Q 05 Nov 2020 2020 Q3
Q2 2019 $1,181,000 $433,000 +$288,000 +199% 01 Apr 2019 30 Jun 2019 10-Q 04 Aug 2020 2020 Q2
Q1 2019 $893,000 $262,000 +$134,000 +105% 01 Jan 2019 31 Mar 2019 10-Q 07 May 2020 2020 Q1
Q4 2018 $759,000 $288,000 +$423,000 01 Oct 2018 31 Dec 2018 10-K 19 Mar 2021 2020 FY
Q3 2018 $336,000 $198,000 -$75,000 -27% 01 Jul 2018 30 Sep 2018 10-Q 07 Nov 2019 2019 Q3
Q2 2018 $411,000 $145,000 -$27,000 -16% 01 Apr 2018 30 Jun 2018 10-Q 07 Aug 2019 2019 Q2
Q1 2018 $438,000 $128,000 -$54,000 -30% 01 Jan 2018 31 Mar 2018 10-Q 15 May 2019 2019 Q1
Q4 2017 $492,000 $135,000 01 Oct 2017 31 Dec 2017 10-K 12 Mar 2020 2019 FY
Q3 2017 $273,000 01 Jul 2017 30 Sep 2017 10-Q 09 Nov 2018 2018 Q3
Q2 2017 $172,000 01 Apr 2017 30 Jun 2017 10-Q 13 Aug 2018 2018 Q2
Q1 2017 $182,000 01 Jan 2017 31 Mar 2017 10-Q 10 May 2018 2018 Q1

X4 Pharmaceuticals, Inc Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $8,204,000 -$483,000 -5.6% 01 Jan 2024 31 Dec 2024 10-K 26 Mar 2025 2024 FY
2023 $8,687,000 +$3,488,000 +67% 01 Jan 2023 31 Dec 2023 10-K 26 Mar 2025 2024 FY
2022 $5,199,000 -$981,000 -16% 01 Jan 2022 31 Dec 2022 10-K 26 Mar 2025 2024 FY
2021 $6,180,000 +$752,000 +14% 01 Jan 2021 31 Dec 2021 10-K 21 Mar 2024 2023 FY
2020 $5,428,000 +$3,378,000 +165% 01 Jan 2020 31 Dec 2020 10-K 21 Mar 2023 2022 FY
2019 $2,050,000 +$1,291,000 +170% 01 Jan 2019 31 Dec 2019 10-K 17 Mar 2022 2021 FY
2018 $759,000 +$267,000 +54% 01 Jan 2018 31 Dec 2018 10-K 19 Mar 2021 2020 FY
2017 $492,000 -$152,000 -24% 01 Jan 2017 31 Dec 2017 10-K 12 Mar 2020 2019 FY
2016 $644,000 01 Jan 2016 31 Dec 2016 10-K 11 Mar 2019 2018 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.